Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes
Indexado
WoS WOS:001367374900001
Scopus SCOPUS_ID:85209880835
DOI 10.1016/J.LANA.2024.100952
Año 2024
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background Cholangiocarcinoma (CCA) represents a global health challenge, with rising incidence and mortality rates. This study aimed to elucidate the clinical course and practices of CCA in Latin America. Methods This observational cohort study investigated individuals diagnosed with CCA between 2010 and 2023 at fi ve referral centres across Latin America. Demographic, biochemical, and clinical data were analysed. Findings A total of 309 patients were enrolled, demonstrating a balanced distribution of CCA subtypes (intrahepatic, perihilar, and distal), with Hispanics and Caucasians as the predominant ethnic groups, followed by Africans. Major risk factors identified included age, diabetes, obesity, MASLD, bile duct stones, and cholecystitis. Disparities in overweight/obesity prevalence were noted among CCA subtypes and ethnicities, with higher rates in extrahepatic CCA and among Hispanics and Caucasians. At diagnosis, 72% of patients had ECOG-PS scores of 0-1, with disease presentations ranging from localized (47%) to locally advanced (19%) and metastatic (34%). Patients who did not receive any anti-cancer therapy exhibited a median survival of 2.3 months. Survival rates significantly improved across treatment modalities, with surgery yielding the longest (34 months), followed by chemotherapy (8 months). Notably, Africans presented with worse ECOG-PS scores and more advanced disease, while Hispanics were less frequently treated with chemotherapy for advanced disease, contributing to lower survival rates (8.3 and 6 months, respectively) compared to Caucasians (12.6 months). Interpretation The high prevalence of late-stage CCA diagnosis in Latin America, particularly among individuals of African ethnicity, coupled with a significant proportion of Hispanic patients not receiving chemotherapy, underscores the dismal prognosis for these patients. These fi ndings reveal structural challenges in cancer screening and healthcare access among diverse ethnic backgrounds and lower socioeconomic statuses in the region. Urgent measures are needed, including the identification of preventable risk factors, raising awareness among high-risk populations, and establishing equitable health coverage to address these disparities.

Revista



Revista ISSN
2667-193X

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Public, Environmental & Occupational Health
Health Care Sciences & Services
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 da Fonseca, Leonardo G. - UNIV SAO PAULO - Brasil
Universidade de São Paulo - Brasil
2 Izquierdo-Sanchez, Laura - Univ Basque Country UPV EHU - España
ISCIII - España
Osakidetza, Donostia University Hospital - España
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España
3 Hashizume, Pedro H. - Universidade de São Paulo - Brasil
4 Carlino, Yanina - Instituto Universitario de Ciencias Biomédicas de Córdoba - Argentina
5 Baca, Estefania Liza - Universidad de San Martín de Porres - Perú
6 Zambrano, Cristina - Hosp Especialidades Carlos Andrade Marin - Ecuador
Hospital de Especialidades Carlos Andrade Marín - Ecuador
7 Sepulveda, Santiago A. Hombre Facultad de Medicina - Chile
8 Bolomo, Andrea - Instituto Universitario de Ciencias Biomédicas de Córdoba - Argentina
9 Rodrigues, Pedro M. - Univ Basque Country UPV EHU - España
ISCIII - España
Osakidetza, Donostia University Hospital - España
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España
Ikerbasque, Basque Foundation for Science - España
10 Riano, Ioana - Univ Basque Country UPV EHU - España
ISCIII - España
Osakidetza, Donostia University Hospital - España
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España
11 Boonstra, Andre Hombre Erasmus MC - Países Bajos
12 Debes, Jose D. - Erasmus MC Univ Med Ctr - Países Bajos
Univ Minnesota - Estados Unidos
Erasmus MC - Países Bajos
School of Public Health - Estados Unidos
University of Minnesota Medical School - Estados Unidos
13 Bujanda, Luis - Univ Basque Country UPV EHU - España
ISCIII - España
Osakidetza, Donostia University Hospital - España
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España
14 Carrilho, Flair J. - Universidade de São Paulo - Brasil
15 ARRESE-JIMENEZ, MARCO ANTONIO Hombre Facultad de Medicina - Chile
16 Roa, Juan C. - Pontificia Universidad Católica de Chile - Chile
Facultad de Medicina - Chile
Instituto Milenio de Inmunología e Inmunoterapia - Chile
17 Carrera, Enrique Hombre Universidad San Francisco de Quito - Ecuador
18 Ferrer, Javier Diaz - Universidad de San Martín de Porres - Perú
19 Balderramo, Domingo - Instituto Universitario de Ciencias Biomédicas de Córdoba - Argentina
20 Oliveira, Claudia P. - UNIV SAO PAULO - Brasil
Universidade de São Paulo - Brasil
21 Banales, Jesus M. Hombre Univ Basque Country UPV EHU - España
ISCIII - España
Basque Fdn Sci - España
Univ Navarra - España
Osakidetza, Donostia University Hospital - España
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España
Ikerbasque, Basque Foundation for Science - España
Universidad de Navarra - España

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
European Union
Horizon 2020
Servier
Horizon 2020 Framework Programme
Jazz Pharmaceuticals
European Association for the Study of the Liver
European Network for the Study of Cholangiocarcinoma
European Association for the Study of the Liver (EASL)
Incyte Bioscience International Sarl
ERN-Rare
Horizon 2020 R&I Program
International Cholangiocarcinoma
Ikan-Biotech
European Reference Network on Rare Liver Diseases
International Primary Sclerosing Cholangitis Study Group
Asociación Española de Gastroenterología

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
Funding European Union's Horizon 2020 R&I Program, Incyte Bioscience International Sarl, and European Association for the Study of the Liver (EASL) .
Authors express their gratitude to the patients and their families for their invaluable participation in this study. Special thanks are extended to Ms. Miren Maitane Gazta\u00F1aga Otermin, Ms. Mar\u00EDa Teresa Eizagirre Urresti, and their families for their generous donations to the Registry study. The authors acknowledge the Asociaci\u00F3n Espa\u00F1ola de Gastroenterolog\u00EDa (AEG) for the REDCap database license and training. Additionally, sincere appreciation is extended to Alvaro Alcar\u00E1z and Enzo Giordano for their technical support of the registry in Cordoba, Argentina. This article is based on work conducted by the ESCALON consortium ( https://escalon.eu/ ), supported by the European Union\u2019s Horizon 2020 Research and Innovation Program [grant number 825510], in collaboration with the European Network for the Study of Cholangiocarcinoma (ENSCCA: http://www.enscca.org/ ), the International Primary Sclerosing Cholangitis Study Group (iPSCSG: https://www.ipscsg.org/ ), the European Reference Network on Rare Liver Diseases (ERN-Rare Liver: https://rare-liver.eu/ ), and the European Reference Network on Rare Adult Cancers (solid tumours; EURACAN: https://euracan.eu/ ).
The LATAM-CCA Registry, which is part of the International Cholangiocarcinoma (INT-CCA) Registry, was competitively funded by the European Union\u2019s Horizon 2020 Research and Innovation Program [grant number 825510, ESCALON], Incyte Bioscience International S\u00E0rl (grant awards 2020 and 2023 to JMB.), and the European Association for the Study of the Liver (EASL; Registry grant awards 2016, 2019 and 2023 to JMB.). Other funding sources: Instituto de Salud Carlos III (ISCIII) [FORT23/00026, FIS PI18/01075, PI21/00922 and Miguel Servet Program CPII19/00008 to JMB; Sara Borrell CD19/00254 and Miguel Servet Program CP22/00073 to PMR.) co-funded by the European Union. \u201CFundaci\u00F3n Cient\u00EDfica de la Asociaci\u00F3n Espa\u00F1ola Contra el C\u00E1ncer\u201D (AECC \u201CRare Cancer\u201D grant AECC17/302 to JMB, and AECC Postdoctoral grant POSTD246369IZQU to LI-S), Asociaci\u00F3n Espa\u00F1ola para el Estudio del H\u00EDgado (AEEH, Juan Rodes Postdoctoral grant to LI-S). PSC Partners US (to JMB) and PSC Supports UK (to JMB). AMMF-The Cholangiocarcinoma Charity (to JMB and PMR). \u201CDiputaci\u00F3n Foral Gipuzkoa\u201D (2020-CIEN-000067-01, 2021-CIEN-000029-04-01 and 2023-CIEN-000008-01 to PMR); Department of Health (2022111070 to PMR; 2017111010, 2019222054, 2020333010, 2020111077, 2022333032, 2023333005 to JMB), and Department of Education (POS_2022_1_0041 to LI-S) of the Basque Country. Pontificia Universidad Cat\u00F3lica de Chile (PBV2302 to MA) and Chilean Government through Fondo Nacional de Desarrollo Cient\u00EDfico y Tecnol\u00F3gico, (Fondecyt Project, 1241450 to MA, and Fondecyt 1221345 to SAS). Millennium Institute on Immunology and Immunotherapy (ICN09_016 and ICN 2021_045 to JCR). The funding sources were not involved in study design, data collection and analysis, decision to publish, or preparation of the article. Moreover, JMB declares research grants (from Incyte, Albireo, and Cymabay), personal fees for lecturer (from Incyte, Astra Zeneca, Intercept, Eisai and Advance), and consulting role (for Albireo, Ipsen, Cymabay, Astra Zeneca, Jazz Pharmaceuticals, Servier, Ikan-Biotech, OWL-Rubi\u00F3 Metabolomics). MA declares personal fees for lecturer (from Siemens and Echosens), and consulting fee (for Inventiva). The remaining authors have no conflicts to report. The funding sources had no involvement in study design, data collection and analysis, decision to publish, or article preparation.
Authors express their gratitude to the patients and their families for their invaluable participation in this study. Special thanks are extended to Ms. Miren Maitane Gazta\u00F1aga Otermin, Ms. Mar\u00EDa Teresa Eizagirre Urresti, and their families for their generous donations to the Registry study. The authors acknowledge the Asociaci\u00F3n Espa\u00F1ola de Gastroenterolog\u00EDa (AEG) for the REDCap database license and training. Additionally, sincere appreciation is extended to Alvaro Alcar\u00E1z and Enzo Giordano for their technical support of the registry in Cordoba, Argentina. This article is based on work conducted by the ESCALON consortium ( https://escalon.eu/ ), supported by the European Union\u2019s Horizon 2020 Research and Innovation Program [grant number 825510], in collaboration with the European Network for the Study of Cholangiocarcinoma (ENSCCA: http://www.enscca.org/ ), the International Primary Sclerosing Cholangitis Study Group (iPSCSG: https://www.ipscsg.org/ ), the European Reference Network on Rare Liver Diseases (ERN-Rare Liver: https://rare-liver.eu/ ), and the European Reference Network on Rare Adult Cancers (solid tumours; EURACAN: https://euracan.eu/ ).

Muestra la fuente de financiamiento declarada en la publicación.